The nomination period is underway for the Buzz of BIO contest at the 2021 BIO CEO & Investor Digital Conference! Winners receive a complimentary conference registration and company presentation as well as increased promotion to industry leaders and investors via BIO’s marketing channels.
Now in its 20th year, the BIO CEO & Investor Conference is one of the largest independent investor conferences focused on established and emerging publicly traded and select private biotech companies. The virtual 2021 event, taking place February 16-18 will present a broad and unbiased view of investment opportunities, BIO’s perspective on the new U.S. Congressional agenda, the record setting pacing of biotech IPOs and the hottest clinical developments and industry catalysts.
Biotechnology researchers, emerging companies, and a wide range of pharmaceuticals have issued an unprecedented response to the pandemic. The results and the pace of innovation are not lost on investors anxious to see what new vaccines and treatments will emerge to address a disease impacting the entire globe. But it is not only the obvious financial reward they anticipate. Investors are like the rest of us—they want to see an end to the crisis, and they are looking for breakthroughs that will improve health outcomes.
While the pandemic rages, the pace of biopharmaceutical innovation in areas outside of infectious disease has not slowed. BIO CEO & Investor Conference is an opportunity for investors to review the entire landscape of emerging companies. Yearly enthusiasm for the Buzz of BIO contest reflects this broad array of exciting pipelines, providing visibility for early-stage companies looking for their next financing round or late-stage private companies hoping to make the connections needed to take their product to the next phase.
Five (5) biotechs will be nominated in each of three categories:
- Public Therapeutic Biotech
- Private Therapeutic Biotech
- Diagnostics and Beyond
To qualify for the “Public Therapeutic Biotech” category, companies must be actively developing a therapeutic product intended for FDA review that addresses human health issues and must be publicly traded
To qualify for the “Private Therapeutic Biotech” category, companies must be actively developing a therapeutic product intended for FDA review that addresses human health issues and must have raised at least $25MM by November 2020, but must not yet be publicly traded.
To qualify for the “Diagnostics and Beyond” category, companies must be primarily focused on medical diagnostics, drug delivery, drug development tools, or digital health technologies.
The first five (5) qualifying completed entries in each category will become contest finalists eligible to receive the Grand Prize. Nominations close at 5:00 p.m. ET on November 15th, and voting opens December 9th.
Please note that this contest is restricted to companies headquartered in the U.S. Read the official contest rules here.
Media registration is also available for qualified members of the press.
.png){kind=logo}
